A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology.
There is an ongoing need for healthy volunteers in clinical research studies that can lead to healthcare breakthroughs that provide better drugs and treatments for patients.
TRIUMF, Canada’s particle accelerator centre, and Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, are pleased to announce that they have agreed to pursue a strategic partnership around the commercial production of Actinium-225, a rare medical isotope that has the potential to serve as the basis of new ground-breaking cancer treatments.
In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson’s disease psychosis, researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system concluding that the new drug, pimavanserin (marketed as Nuplazid), did not pose a statistically significant greater risk of death.
.Johns Hopkins School of Nursing’s (JHSON) Cynda Rushton, PhD, RN, FAAN, has been chosen to serve on a newly formed National Academies of Science, Engineering, and Medicine committee to develop recommendations for systemic solutions to combating clinician burnout. Rushton was one of only two nurses selected for the committee.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug—one with no known medical potential—to a schedule IV drug such as prescription sleep aids, but with tighter control.
CU Boulder researchers have identified a family of small molecules that turn off defense mechanisms inside bacteria that enable them to resist antibiotics. The compounds could ultimately be given alongside existing medications to rejuvenate them.
Restricting protein from a cancer patient’s diet may enhance the response to immunotherapy, according to an Indiana University cancer physician researcher.
A team of researchers including UCI project scientist Rachita Sumbria, PhD and UCI neurologist Mark J. Fisher, MD have provided, for the first time, evidence that blood deposits in the brain may not require a blood vessel tear.
Media can get a quick overview of what the CAP does, how it's expert member pathologists can add value to their stories.
A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, according to a study led by Cedars-Sinai. The study also demonstrated in mice that the drug, Metavert, may prevent patients from developing a resistance to currently used pancreatic cancer chemotherapies.
A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide unprecedented response rates among stage 4 non-small cell lung cancer patients with genetic mutations that have previously defied treatment.
Clinical trials that support FDA approvals of new drugs have a median cost of $19 million, according to a new study by a team including researchers from Johns Hopkins Bloomberg School of Public Health.
Using a clinical checklist to identify eligible patients, doctors were able to shorten the antibiotic duration for patients with uncomplicated staphylococcal bloodstream infections by nearly two days, Duke Health researchers report.
Patients treated with more-invasive surgical techniques for a type of early-stage lung cancer are more likely to become chronic opioid users than patients treated with minimally invasive surgery.
ISPOR, the professional society for health economics and outcomes research, announced plenary sessions and speakers for ISPOR Europe 2018, “New Perspectives for Improving 21st Century Health Systems." The conference is scheduled for 10-14 November in Barcelona, Spain.
Certified Registered Nurse Anesthetists (CRNAs) and other healthcare professionals will gather and discuss issues and solutions for enhanced recovery after surgery, access to quality anesthesia care, and technology’s role in healthcare, among other topics during the Nurse Anesthesia Annual Congress of the American Association of Nurse Anesthetists (AANA), Sept. 21-25, 2018, in Boston, Mass.
The inaugural lecture on diversity and inclusion is named after the American Association of Nurse Anesthetists’ 1973-1974 President, Goldie D. Brangman, MEd, MBA, CRNA. Brangman is the first and only African-American President of the AANA and will celebrate her 101st birthday in October.
This first randomized clinical study of a polymer-coated zotarolimus-eluting stent (Resolute Onyx) that utilizes a novel thin-strutted metallic platform allowing for better x-ray visibility was shown to be non-inferior to an ultrathin-strutted bioresorbable polymer-coated sirolimus-eluting stent (Orsiro) that uses a cobalt-chromium strut platform.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right